Edwards Lifesciences Corp (EW) : Partner Investment Management reduced its stake in Edwards Lifesciences Corp by 13.18% during the most recent quarter end. The investment management company now holds a total of 19,693 shares of Edwards Lifesciences Corp which is valued at $1,705,217 after selling 2,990 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Edwards Lifesciences Corp makes up approximately 2.92% of Partner Investment Management’s portfolio.
Other Hedge Funds, Including , Capital Research Global Investors reduced its stake in EW by selling 220,000 shares or 3.31% in the most recent quarter. The Hedge Fund company now holds 6,427,014 shares of EW which is valued at $556,515,142. Edwards Lifesciences Corp makes up approx 0.20% of Capital Research Global Investors’s portfolio.De Burlo Group Inc reduced its stake in EW by selling 30,500 shares or 27.93% in the most recent quarter. The Hedge Fund company now holds 78,700 shares of EW which is valued at $7,307,295. Edwards Lifesciences Corp makes up approx 2.12% of De Burlo Group Inc’s portfolio.Ngam Advisors boosted its stake in EW in the latest quarter, The investment management firm added 31 additional shares and now holds a total of 23,626 shares of Edwards Lifesciences Corp which is valued at $2,117,598. Edwards Lifesciences Corp makes up approx 0.03% of Ngam Advisors’s portfolio. Next Financial Group Inc added EW to its portfolio by purchasing 545 company shares during the most recent quarter which is valued at $48,347. Edwards Lifesciences Corp makes up approx 0.01% of Next Financial Group Inc’s portfolio.
Edwards Lifesciences Corp closed down -1.69 points or -1.86% at $89.03 with 17,16,858 shares getting traded on Monday. Post opening the session at $90.81, the shares hit an intraday low of $88.81 and an intraday high of $90.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Edwards Lifesciences Corp reported $0.68 EPS for the quarter, based on the information available during the earnings call on Oct 25, 2016. Analyst had a consensus estimate of $0.68. The company had revenue of $739.40 million for the quarter, compared to analysts expectations of $749.07 million. The company’s revenue was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Shares were Reiterated by RBC Capital Mkts on Oct 26, 2016 to “Outperform” and Lowered the Price Target to $ 123 from a previous price target of $130 .Shares were Reiterated by Stifel on Oct 26, 2016 to “Buy” and Lowered the Price Target to $ 114 from a previous price target of $122 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.